Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
-Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis-
Source: eagletribune.com
Global Project Head News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Global Project Head. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Global Project Head Today - Breaking & Trending Today
JLSR Wellness Pvt Ltd launches UrbOx - A Smart and Sensible Oxygen Optimizer for Improved Indoor Air Quality
New Delhi [India], November 1 (ANI/PNN): JLSR Wellness Pvt Ltd launches UrbOx - a one-of-its-kind smart and sensible oxygen Optimizer. UrbOx is an indoor oxygen optimizer that aims to solve the indoor suffocation issue with pure oxygen. Its world-class sensors optimize the amount of oxygen in the indoor air and help to maintain a healthy level of oxygen in your sealed homes and offices. UrbOx increases the level of oxygen to 20-25 per cent to eliminate any risk of health hazards caused by indoor suffocation. The device is not a purifier; it's beyond a purifier. UrbOx is a one-time install ...
Source: laosnews.net
Will Europe Lead in RSV Prevention
RSV prevention includes vaccines candidates and antibody treatment
Source: precisionvaccinations.com
Editas Medicine Announces Second Quarter 2022 Results and Business Updates
03.08.2022 - Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior leadership team Achieved successful engraftment of first patient treated with EDIT-301 for sickle cell disease; first clinical use of Editas-engineered AsCas12a ...
Source: wallstreet-online.de
Axcella Announces Alison D. Schecter, M.D., as President of R&D
Experienced biopharma leader to oversee research, candidate development, clinical and regulatory functions CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the appointment of Alison D. Schecter, M.D., as the company’s President of Research and Development. In this role, Dr. Schecter will oversee all of the company’s research, product candidate design, clinical and regulatory efforts. Additionally, Ma...
Source: pharmiweb.com